{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:19Z","timestamp":1753891339848,"version":"3.41.2"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The field of antiviral therapeutics is fixated on COVID19 and rightly so as the fatalities at the height of the pandemic in the United States were almost 1,000,000 in a twelve month period spanning parts of 2020\/2021.\u00a0A coronavirus called SARS\u2013CoV2 is the causative virus. Development of a vaccine through molecular biology approaches with mRNA as the inducer of virus spike protein has played a major role in driving down mortality and morbidity. Antivirals have been of marginal value in established infections at the level of hospitalization. Thus, the current focus is on early symptomatic infection of about the first five days. The Pfizer drug paxlovid which is composed of nirmatrelvir, a peptidomimetic protease inhibitor of SARS\u2013CoV2 Mpro enzyme, and ritonavir to retard degradation of nirmatrelvir, is the current FDA recommended treatment of early COVID19. There is no evidence of broad antiviral activity of paxlovid against other diverse viruses such as the influenza virus, poxviruses, as well as a host of respiratory viruses. Although type I interferons (IFNs) are effective against SARS\u2013CoV2 in cell cultures and in early COVID19 infections, they have not been broadly recommended as therapeutics for COVID19. We have developed stable peptidomimetics of both types I and II IFNs based on our noncanonical model of IFN signaling involving the C-terminus of the IFNs. We have also identified two members of intracellular checkpoint inhibitors called suppressors of cytokine signaling (SOCS), SOCS1 and SOCS3 (SOCS1\/3), and shown that they are virus induced intrinsic virulence proteins with activity against IFN signaling enzymes JAK2 and TYK2. We developed a peptidomimetic antagonist, based on JAK2 activation loop, against SOCS1\/3 and showed that it synergizes with the IFN mimetics for potent broad spectrum antiviral activity without the toxicity of intact IFN molecules. IFN mimetics and the SOCS1\/3 antagonist should have an advantage over currently used antivirals in terms of safety and potency against a broad spectrum of viruses.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1208828","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:40:41Z","timestamp":1701438041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Disparate viral pandemics from COVID19 to monkeypox and beyond: a simple, effective and universal therapeutic approach hiding in plain sight"],"prefix":"10.3389","volume":"14","author":[{"given":"Howard M.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chulbul M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jmii.2020.09.002","article-title":"Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review","volume":"54","author":"Yang","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/v14061345","article-title":"Repurposing molnupiravir for COVID-19: the mechanisms of antiviral activity","volume":"14","author":"Yip","year":"2022","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","first-page":"112517","DOI":"10.1016\/j.biopha.2021.112517","article-title":"RdRp inhibitors and COVID-19: Is molnupiravir a good option","volume":"146","author":"Hashemian","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.855496","article-title":"Molnupiravir and its antiviral activity against COVID-19","volume":"13","author":"Tian","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.909","article-title":"Molnupiravir: A new candidate for COVID-19 treatment","volume":"10","author":"Pourkarim","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101972","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102252","DOI":"10.1016\/j.coi.2022.102252","article-title":"Insights into pandemic respiratory viruses: manipulation of the antiviral interferon response by SARS-CoV-2 and influenza A virus","volume":"78","author":"Liu","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.582102","article-title":"SOCS, intrinsic virulence factors, and treatment of COVID-19","volume":"11","author":"Johnson","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cytogfr.2021.12.001","article-title":"Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19","volume":"63","author":"Aric\u00f2","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2021-0243","article-title":"Identifying asymptomatic cases during the mass COVID-19 vaccination campaign: insights and implications for policy makers","author":"Chirico","year":"2021","journal-title":"Future Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167042","article-title":"Interferon-dependent signaling is critical for viral clearance in airway neutrophils","volume":"8","author":"Margaroli","year":"2023","journal-title":"JCI Insight"},{"key":"B19","unstructured":"Coronavvirus disease 2019 (COVID), treatment guidelines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2022.2008910","article-title":"Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective","volume":"16","author":"Cojocaru","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41577-022-00775-4","article-title":"Monkeypox: disease epidemiology, host immunity and clinical interventions","volume":"22","author":"Lum","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a010199","article-title":"Poxvirus DNA replication","volume":"5","author":"Moss","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J Gen Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00202","article-title":"IFN signaling: how a non-canonical model led to the development of IFN mimetics","volume":"4","author":"Johnson","year":"2013","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0041","article-title":"Short Peptide type I interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infections","volume":"34","author":"Ahmed","year":"2014","journal-title":"J Interferon Cytokine Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00183","article-title":"SOCS1 mimetics and antagonists: A complementary approach to positive and negative regulation of immune function","volume":"6","author":"Ahmed","year":"2015","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nrm3920","article-title":"Intrinsically disordered proteins in cellular signalling and regulation","volume":"16","author":"Wright","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10858-019-00280-2","article-title":"Perspective: the essential role of NMR in the discovery and characterization of intrinsically disordered proteins","volume":"73","author":"Dyson","year":"2019","journal-title":"J Biomol NMR"},{"key":"B31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.sbi.2021.03.015","article-title":"NMR illuminates intrinsic disorder","volume":"70","author":"Dyson","year":"2021","journal-title":"Curr Opin Struct Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.129.6.2357","article-title":"Neutralization of native human gamma interferon (HuIFN gamma) by antibodies to a synthetic peptide encoded by the 5' end of HuIFN gamma cDNA","volume":"129","author":"Johnson","year":"1982","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/107999001753289569","article-title":"Nuclear translocation of IFN-gamma is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence","volume":"21","author":"Subramaniam","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.1.403","article-title":"The carboxyl terminus of interferon-gamma contains a functional polybasic nuclear localization sequence","volume":"274","author":"Subramaniam","year":"1999","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/10799900050044769","article-title":"Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-gamma receptor complex following activation by IFN-gamma","volume":"20","author":"Larkin","year":"2000","journal-title":"J Interferon Cytokine Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.4.1959","article-title":"Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gamma, its receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear translocation of STAT1alpha","volume":"169","author":"Subramaniam","year":"2002","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4143604","DOI":"10.1155\/2019\/4143604","article-title":"Noncanonical IFN signaling, steroids, and STATs: A probable role of V-ATPase","volume":"2019","author":"Johnson","year":"2019","journal-title":"Mediators Inflamm"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.12.5617","article-title":"Identification of IFN-gamma receptor binding sites for JAK2 and enhancement of binding by IFN-gamma and its C-terminal peptide IFN-gamma(95-133)","volume":"155","author":"Szente","year":"1995","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/bies.20086","article-title":"Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors","volume":"26","author":"Johnson","year":"2004","journal-title":"Bioessays"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20112187","article-title":"Steroid-like signalling by interferons: making sense of specific gene activation by cytokines","volume":"443","author":"Johnson","year":"2012","journal-title":"Biochem J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"9564814","DOI":"10.1155\/2016\/9564814","article-title":"Noncanonical IFN signaling: mechanistic linkage of genetic and epigenetic events","volume":"2016","author":"Johnson","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1691","article-title":"Binding of IFN gamma and its C-terminal peptide to a cytoplasmic domain of its receptor that is essential for function","volume":"201","author":"Szente","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2375","article-title":"The C-terminus of IFN gamma is sufficient for intracellular function","volume":"203","author":"Szente","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.10.085","article-title":"The IFNAR1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence","volume":"578","author":"Subramaniam","year":"2004","journal-title":"FEBS Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.10.006","article-title":"Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy","volume":"254","author":"Ahmed","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.26.12270","article-title":"Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities","volume":"92","author":"Subramaniam","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00204-14","article-title":"Type I interferon mimetics bypass vaccinia virus decoy receptor virulence factor for protection of mice against lethal infection","volume":"21","author":"Ahmed","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4576","article-title":"IFN mimetic as a therapeutic for lethal vaccinia virus infection: possible effects on innate and adaptive immune responses","volume":"178","author":"Ahmed","year":"2007","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00021-06","article-title":"The gamma interferon (IFN-gamma) mimetic peptide IFN-gamma (95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice","volume":"13","author":"Mujtaba","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01857-10","article-title":"Viral exploitation of host SOCS protein functions","volume":"85","author":"Akhtar","year":"2011","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102010","article-title":"A comprehensive survey of the roles of highly disordered proteins in type 2 diabetes","volume":"18","author":"Du","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5058","article-title":"Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist","volume":"178","author":"Waiboci","year":"2007","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00574","article-title":"A SOCS1\/3 antagonist peptide protects mice against lethal infection with influenza A virus","volume":"6","author":"Ahmed","year":"2015","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.902956","article-title":"Individual and synergistic anti-coronavirus activities of SOCS1\/3 antagonist and interferon \u03b11 peptides","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902895","article-title":"Enhancement of antiviral immunity by small molecule antagonist of suppressor of cytokine signaling","volume":"185","author":"Ahmed","year":"2010","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.immuni.2023.03.005","article-title":"Spheromers reveal robust T cell responses to the Pfizer\/BioNTech vaccine and attenuated peripheral CD8","volume":"56","author":"Gao","year":"2023","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00273-8","article-title":"Mpox in people with advanced HIV infection: a global case series","volume":"401","author":"Mitj\u00e0","year":"2023","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.08.010","article-title":"Increased expression of negative regulators of cytokine signaling during chronic HIV disease cause functionally exhausted state of dendritic cells","volume":"91","author":"Sachdeva","year":"2017","journal-title":"Cytokine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009387","article-title":"SOCS-1 inhibition of type I interferon restrains Staphylococcus aureus skin host defense","volume":"17","author":"Klopfenstein","year":"2021","journal-title":"PloS Pathog"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2205944","article-title":"Nirmatrelvir-ritonavir and viral load rebound in covid-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.07.499047","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1208828\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:40:45Z","timestamp":1701438045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1208828\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2023.1208828"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1208828","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1208828"}}